Your browser doesn't support javascript.
loading
Exploiting protease activation for therapy.
Bleuez, Chloe; Koch, Wolfgang F; Urbach, Carole; Hollfelder, Florian; Jermutus, Lutz.
Afiliación
  • Bleuez C; Research & Early Development, Cardiovascular, Renal & Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge, UK.
  • Koch WF; Research & Early Development, Cardiovascular, Renal & Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge, UK.
  • Urbach C; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Hollfelder F; Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge, UK.
  • Jermutus L; Research & Early Development, Cardiovascular, Renal & Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Electronic address: lutz.jermutus@astrazeneca.com.
Drug Discov Today ; 27(6): 1743-1754, 2022 06.
Article en En | MEDLINE | ID: mdl-35314338
Proteases have crucial roles in homeostasis and disease; and protease inhibitors and recombinant proteases in enzyme replacement therapy have become key therapeutic applications of protease biology across several indications. This review briefly summarises therapeutic approaches based on protease activation and focuses on how recent insights into the spatial and temporal control of the proteolytic activation of growth factors and interleukins are leading to unique strategies for the discovery of new medicines. In particular, two emerging areas are covered: the first is based on antibody therapies that target the process of proteolytic activation of the pro-form of proteins rather than their mature form; the second covers a potentially new class of biopharmaceuticals using engineered, proteolytically activable and initially inactive pro-forms of antibodies or effector proteins to increase specificity and improve the therapeutic window.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptido Hidrolasas / Inhibidores de Proteasas Idioma: En Revista: Drug Discov Today Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptido Hidrolasas / Inhibidores de Proteasas Idioma: En Revista: Drug Discov Today Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article
...